Ex-vivo sensitivity profiling to guide clinical decision making in acute myeloid leukemia: A pilot study

Area of Science:

• Oncology
• Pharmacology
• Genetics

Background:

• Precision medicine offers potential for acute myeloid leukemia (AML) due to tumor accessibility and variable treatment responses.
• Previous AML precision medicine platforms faced limitations with small compound panels and slow turnaround times, hindering treatment scope and initiation.
• Refractory AML presents a critical need for effective, personalized therapeutic strategies.

Purpose of the Study:

• To evaluate the efficacy of an ex vivo drug sensitivity testing (DST) platform for guiding treatment in refractory AML.
• To assess the impact of DST-guided therapy on patient survival and treatment response.

Main Methods:

• A pilot study involving 12 refractory AML patients.
• Ex vivo screening of purified AML blasts against a panel of 215 FDA-approved compounds.
• Evaluation of drug sensitivity after 72-hour exposure and reporting of scores to physicians.
• Comparison of outcomes between DST-guided and non-DST-guided therapy.

Main Results:

• Patients receiving DST-guided therapy demonstrated a survival benefit compared to those receiving physician-recommended therapy.
• Three of four patients treated with DST-guided therapy showed a positive treatment response.
• All patients receiving non-DST-guided therapy experienced disease progression.

Conclusions:

• Ex vivo drug sensitivity testing (DST) provides a rapid and effective method for generating personalized treatment recommendations in refractory AML.
• DST platforms can overcome previous limitations, enabling timely and targeted therapeutic interventions.
• This pilot study supports the clinical utility of DST in optimizing treatment strategies for AML patients.